Lindsay A. Rosenwald, M.D. – Executive Chairman of the Board of Directors
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as Cyprium’s Executive Chairman, Dr. Rosenwald is Chairman and CEO of Fortress Biotech, Cyprium’s parent company, and a member of Fortress’ Board of Directors. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm that is affiliated with Fortress. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.
Lung S. Yam, M.D., Ph.D., Chief Executive Officer
Lung S. Yam, M.D., Ph.D., Chief Executive Officer of Cyprium. co-founded Cyprium as part of his role as a Business Development Consultant for Fortress, where he identified multiple opportunities across diverse therapeutic areas leading to the in-licensing of multiple assets, including CUTX-101 and the AAV-ATP7A gene therapy program. In addition to his roles at Cyprium and Fortress, Dr. Yam serves as Senior Advisor at Opus Point Partners, LLC, an affiliated life-science focused asset management firm. Prior to joining Opus Point Partners, Dr. Yam was an equity research associate at Rodman & Renshaw, LLC. Dr. Yam earned M.D. and Ph.D. degrees from New York University School of Medicine, and a B.A. in biology from Johns Hopkins University, where he graduated Phi Beta Kappa.